Core Insights - Apellis Pharmaceuticals reported a year of disciplined execution and foundation building, driven by strong demand for its geographic atrophy therapy Syfovre and the early launch of Empaveli in rare kidney diseases [5] Financial Performance - Total revenue for the fourth quarter was $200 million, with full-year revenue reaching $1.0 billion for 2025, including a one-time $275 million payment related to a royalty repurchase agreement [4] - Syfovre generated $155 million in net product revenue for the fourth quarter and $587 million for the full year, with total injections increasing approximately 17% year-over-year [3][2] - Empaveli achieved $35 million in U.S. net product revenue in the fourth quarter and $102 million for the full year 2025, with over 5% market penetration after its first full quarter [3][9] Product Developments - The company is working on a prefilled syringe for Syfovre, with regulatory submission expected in the first half of 2026, aimed at improving convenience in retina clinics [7][8] - An AI-enabled tool called Functional OCT is being developed to visualize functional benefits in geographic atrophy, with plans for research use in the second half of 2026 [7][8] Market Position and Strategy - Syfovre continues to lead the geographic atrophy market, with strong payer coverage and preferred status across various plans [2] - The company is focusing on expanding patient identification and diagnosis through targeted medical education and increasing urgency for earlier treatment [13] Pipeline Updates - Apellis has initiated pivotal trials for Empaveli in focal segmental glomerulosclerosis and delayed graft function, addressing high unmet needs in kidney indications [11] - The company is also advancing earlier-stage programs, including a Phase 2 combination study with Syfovre and APL-3007, with top-line data expected in 2027 [14] Financial Position - Operating expenses for the fourth quarter were $251 million, consistent with the previous year, and the company ended 2025 with $466 million in cash and cash equivalents, providing flexibility for future operations [11] - Apellis has approximately $94 million of convertible debt maturing in September and is evaluating alternatives to address this obligation [12]